Jeffrey Hung
Stock Analyst at Morgan Stanley
(2.36)
# 2,520
Out of 4,944 analysts
214
Total ratings
40.48%
Success rate
-0.37%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jeffrey Hung
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BCYC Bicycle Therapeutics | Maintains: Equal-Weight | $17 → $13 | $7.82 | +66.24% | 6 | Aug 12, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Overweight | $100 → $109 | $97.43 | +11.88% | 12 | Aug 6, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $165 → $162 | $114.76 | +41.16% | 8 | Aug 6, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Overweight | $150 → $158 | $130.21 | +21.34% | 28 | Jul 31, 2025 | |
| FOLD Amicus Therapeutics | Upgrades: Overweight | $102 → $108 | $7.15 | +1,411.55% | 5 | Jul 17, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $65 → $55 | $28.48 | +93.12% | 9 | Jul 14, 2025 | |
| CGON CG Oncology | Maintains: Overweight | $52 → $56 | $25.26 | +121.69% | 4 | Jun 17, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Equal-Weight | $20 → $24 | $25.30 | -5.14% | 25 | May 20, 2025 | |
| CTNM Contineum Therapeutics | Maintains: Overweight | $25 → $20 | $6.90 | +189.86% | 3 | May 19, 2025 | |
| ENGN enGene Holdings | Maintains: Overweight | $37 → $34 | $3.64 | +834.07% | 3 | Mar 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $67 → $70 | $46.27 | +51.29% | 11 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $4 | $1.67 | +139.52% | 3 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $85 | $60.40 | +40.74% | 6 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $38 → $35 | $7.52 | +365.43% | 6 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $27 | $17.54 | +53.93% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Underweight | $5 | $4.55 | +9.89% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $70 → $67 | $35.68 | +87.78% | 13 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $9.35 | +274.31% | 1 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $70 | $29.41 | +138.01% | 2 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $10 → $4 | $0.82 | +387.21% | 10 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $1 → $4 | $0.77 | +422.74% | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $14 | $3.22 | +335.46% | 3 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $5 | $3.13 | +59.74% | 1 | Jul 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $9 → $3 | $1.93 | +55.44% | 8 | Mar 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $14 | $1.58 | +786.75% | 7 | Feb 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $50 → $10 | $3.12 | +220.51% | 3 | Jan 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $23 → $22 | $38.27 | -42.51% | 10 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $146 → $149 | $13.83 | +973.75% | 2 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $100 → $60 | $1.72 | +3,388.37% | 5 | Aug 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $6 | $3.65 | +64.38% | 9 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $696 → $648 | $4.90 | +13,138.00% | 6 | May 8, 2020 |
Bicycle Therapeutics
Aug 12, 2025
Maintains: Equal-Weight
Price Target: $17 → $13
Current: $7.82
Upside: +66.24%
Rhythm Pharmaceuticals
Aug 6, 2025
Maintains: Overweight
Price Target: $100 → $109
Current: $97.43
Upside: +11.88%
Jazz Pharmaceuticals
Aug 6, 2025
Maintains: Overweight
Price Target: $165 → $162
Current: $114.76
Upside: +41.16%
Neurocrine Biosciences
Jul 31, 2025
Maintains: Overweight
Price Target: $150 → $158
Current: $130.21
Upside: +21.34%
Amicus Therapeutics
Jul 17, 2025
Upgrades: Overweight
Price Target: $102 → $108
Current: $7.15
Upside: +1,411.55%
Ultragenyx Pharmaceutical
Jul 14, 2025
Maintains: Overweight
Price Target: $65 → $55
Current: $28.48
Upside: +93.12%
CG Oncology
Jun 17, 2025
Maintains: Overweight
Price Target: $52 → $56
Current: $25.26
Upside: +121.69%
ACADIA Pharmaceuticals
May 20, 2025
Maintains: Equal-Weight
Price Target: $20 → $24
Current: $25.30
Upside: -5.14%
Contineum Therapeutics
May 19, 2025
Maintains: Overweight
Price Target: $25 → $20
Current: $6.90
Upside: +189.86%
enGene Holdings
Mar 11, 2025
Maintains: Overweight
Price Target: $37 → $34
Current: $3.64
Upside: +834.07%
Mar 7, 2025
Assumes: Overweight
Price Target: $67 → $70
Current: $46.27
Upside: +51.29%
Mar 7, 2025
Assumes: Overweight
Price Target: $4
Current: $1.67
Upside: +139.52%
Mar 7, 2025
Assumes: Overweight
Price Target: $85
Current: $60.40
Upside: +40.74%
Mar 7, 2025
Assumes: Overweight
Price Target: $38 → $35
Current: $7.52
Upside: +365.43%
Mar 7, 2025
Assumes: Overweight
Price Target: $27
Current: $17.54
Upside: +53.93%
Mar 7, 2025
Assumes: Underweight
Price Target: $5
Current: $4.55
Upside: +9.89%
Feb 13, 2025
Upgrades: Overweight
Price Target: $70 → $67
Current: $35.68
Upside: +87.78%
Jul 26, 2024
Initiates: Overweight
Price Target: $35
Current: $9.35
Upside: +274.31%
May 23, 2024
Maintains: Overweight
Price Target: $50 → $70
Current: $29.41
Upside: +138.01%
Dec 19, 2023
Downgrades: Underweight
Price Target: $10 → $4
Current: $0.82
Upside: +387.21%
Dec 19, 2023
Upgrades: Equal-Weight
Price Target: $1 → $4
Current: $0.77
Upside: +422.74%
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $14
Current: $3.22
Upside: +335.46%
Jul 11, 2023
Reiterates: Equal-Weight
Price Target: $5
Current: $3.13
Upside: +59.74%
Mar 20, 2023
Maintains: Equal-Weight
Price Target: $9 → $3
Current: $1.93
Upside: +55.44%
Feb 27, 2023
Maintains: Equal-Weight
Price Target: $15 → $14
Current: $1.58
Upside: +786.75%
Jan 30, 2023
Downgrades: Underweight
Price Target: $50 → $10
Current: $3.12
Upside: +220.51%
Nov 2, 2022
Maintains: Equal-Weight
Price Target: $23 → $22
Current: $38.27
Upside: -42.51%
May 11, 2022
Maintains: Equal-Weight
Price Target: $146 → $149
Current: $13.83
Upside: +973.75%
Aug 13, 2021
Downgrades: Underweight
Price Target: $100 → $60
Current: $1.72
Upside: +3,388.37%
Apr 19, 2021
Maintains: Equal-Weight
Price Target: $7 → $6
Current: $3.65
Upside: +64.38%
May 8, 2020
Maintains: Overweight
Price Target: $696 → $648
Current: $4.90
Upside: +13,138.00%